Last reviewed · How we verify

Shenzhen Ausa Pharmed Co.,Ltd — Portfolio Competitive Intelligence Brief

Shenzhen Ausa Pharmed Co.,Ltd pipeline: 5 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 0 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Amlodipine placebos Amlodipine placebos marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel Cardiovascular
Amlodipine-folic acid placebos Amlodipine-folic acid placebos marketed Calcium channel blocker with vitamin supplement L-type calcium channel (amlodipine); folate metabolism (folic acid) Cardiovascular
Amlodipine besylate and folic acid Amlodipine besylate and folic acid marketed Calcium channel blocker + B vitamin supplement L-type calcium channel (amlodipine); dihydrofolate reductase (folic acid) Cardiovascular
Enalapril maleate and folic acid tablets Enalapril maleate and folic acid tablets marketed ACE inhibitor (combination with vitamin supplement) Angiotensin-converting enzyme (ACE) Cardiovascular
Enalapril/folic acid Enalapril/folic acid marketed ACE inhibitor with vitamin supplement Angiotensin-converting enzyme (ACE) Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 2 shared drug classes
  2. Pfizer Inc. · 2 shared drug classes
  3. Ain Shams University · 1 shared drug class
  4. Beijing Tiantan Hospital · 1 shared drug class
  5. Bioprojet · 1 shared drug class
  6. Boryung Pharmaceutical Co., Ltd · 1 shared drug class
  7. Bristol-Myers Squibb · 1 shared drug class
  8. Bayer · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shenzhen Ausa Pharmed Co.,Ltd:

Cite this brief

Drug Landscape (2026). Shenzhen Ausa Pharmed Co.,Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shenzhen-ausa-pharmed-co-ltd. Accessed 2026-05-16.

Related